In this issue:
- Ofatumumab in recently diagnosed treatment-naïve pwMS
- Rituximab vs dimethyl fumarate in patients with RRMS or clinically isolated syndrome
- Long-term efficacy and safety of siponimod in patients with SPMS
- Safety of glatiramer acetate during breastfeeding
- Serum NfL concentrations after switching from standard to extended-interval dosing of natalizumab
- Immunological consequences of cladribine treatment
- Response to COVID-19 booster vaccinations in pwMS
- Evaluation of liver injury after pulsed steroid therapy for relapse
- Impact of previous DMTs on safety and efficacy of aHSCT
- Time to first treatment and risk of disability pension in RRMS
Please login below to download this issue (PDF)